Red Bull and KW25 to Run Tender Process for New FIA World Rally Championship Commercial Rights Holder
21.8.2025 16:00:00 EEST | Business Wire | Press release
The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, has today announced that a tender process will be run for a new commercial rights holder of the FIA World Rally Championship (WRC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250821560905/en/
FIA World Rally Championship
This follows an extensive period of discussions with Red Bull and KW25, the current commercial rights holders of the FIA World Rally Championship, who have taken the decision to commence the process.
The FIA World Rally Championship has surged in popularity in recent years, with a 1.3bn cumulative television audience and over 4m on-site visitors in 2024. With almost half of those in-person fans between the ages of 18-34, the Championship has huge further growth potential in the years to come. The next round of the Championship is on 28th August at the Rally del Paraguay, which is making its debut as a host country this year.
The FIA’s priority is to ensure that the WRC is best placed to maximise on this potential and deliver value to all its stakeholders, including drivers, teams, manufacturers, organisers and fans, while also preserving its strong heritage.
The FIA will work with Red Bull and KW25 to seek a new commercial rights holder which is committed to long-term investment in the Championship and to securing the best possible future for WRC. This is an exciting opportunity for a new enterprise to take the Championship to the next level and to build out engagement with a new generation of fans.
J.P. Morgan, the global financial services company, will be acting as financial advisor to Red Bull and KW25, supporting them through the tender process.
Mohammed Ben Sulayem, FIA President said:
"The FIA World Rally Championship is at an exciting moment in its history. Millions of fans around the world are following the action, and new, younger audiences are driving its global growth. This Championship has enormous potential, and it is our responsibility as governing body to ensure it continues to grow and reaches new heights.
This process is an important step and will shape the long-term vision for the WRC, and I am confident that, together with the right partner, we can take the championship to the next level, preserve its proud heritage, and grow its global reach for generations of fans to come.”
Malcolm Wilson OBE, FIA Deputy President for Sport, said:
“The FIA World Rally Championship, is the longest-running motorsport series of its kind, one of the most thrilling competitions in the world, with a unique heritage and an exciting growth trajectory ahead. The tender process for the commercial rights holder is a big opportunity for a new enterprise to take the Championship into its next chapter with renewed energy and investment. We will work with Red Bull and KW25 to find the best fit for this important role.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250821560905/en/
Contacts
For media inquiries, please contact:
Jonathan Refoy, Chief Communications Officer: jrefoy@fia.com
Maria Zander, Corporate Communications Manager: mzander@fia.com
Sven Good, Sports Communication Coordinator: sgood@fia.com
Omar Sharif, Sports Communications Manager: osharif@fia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom